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Abstract
Background: Identification of the genes and pathways associated with the activation of endothelial
cells (ECs) could help uncover the role of ECs in wound healing, vascular permeability, blood brain
barrier function, angiogenesis, diabetic retinopathy, atherosclerosis, psoriasis, and growth of solid
tumors.
Design: Herein, we embedded ECs in 3D type I collagen gel, left unstimulated or stimulated with
VEGF165, and subjected to suppression subtractive hybridization followed by differential display
(SSHDD). Gene fragments obtained from SSHDD were subjected to DNA sequence analysis.
Database search with nucleotide sequence were performed using the BLAST algorithm and
expression of candidate genes determined by northern blot analysis.
Results: A total of ~32 cDNA fragments, including known regulators of angiogenesis, and a set of
genes that were not reported to be associated with activation of ECs and angiogenesis previously
were identified. We confirmed the mRNA expression of KDR, α2 integrin, Stanniocalcin, including
a set of 11 candidate genes. Western immunoblotting results indicated that KDR, α2 integrin, MMP-
1, MMP-2, and VE-cadherin genes were indeed active genes.
Conclusion: We have identified a set of 11 VEGF-responsive endothelial cell candidate genes.
Their expression in endothelial cell is confirmed by northern blot analyses. This preliminary report
forms as a foundation for functional studies to be performed to reveal their roles in EC activation
and pathophysiological events associated with the vasculature including tumor growth.
Background
Identification of vascular endothelial growth factor
(VEGF)/vascular permeability factor (VPF)-responsive
genes could potentially help elucidate the detail molecu-
lar mechanisms of endothelial cells (EC) activation. EC
activation is a program of gene-expression that could
affect angiogenesis, permeability, and inflammation that
are closely associated with a large number of vascular dis-
eases. Recent studies show that priming of quiescent ECs
with appropriate cytokines could switch-on the EC tran-
scription machinery, the genes and protein products of
which could activate ECs. Mediators known to activate
ECs include inflammatory cytokines, growth factors such
as VEGF/VPF and basic fibroblast growth factor (bFGF),
extracellular matrix (ECM) proteins such as collagen and
fibronectin, and proteases such as MMPs [1,2]. In vitro and
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in vivo assays indicate that VEGF signaling promotes
increased permeability, cell migration, proliferation, and
differentiation, functioning through two EC-specific tyro-
sine kinase receptor such as Kinase domain receptor
(KDR) [1–3]. In the majority of solid tumors, VEGF is
upregulated in response to hypoxia, inducing the expres-
sion of pro-angiogenic genes that promote tumor angio-
genesis, growth and eventual metastasis [3–5]. The
expression of both positive and negative factors must be
tightly and specifically regulated in a coordinated manner.
Uncontrolled expressions of these factors could activate
the EC transcription machinery, which could promote
pathological consequences including tumor growth and
metastasis [3–6].
Thus, the identification and dissection of the cellular and
molecular pathways associated with EC activation may
reveal novel clues which could provide further under-
standing of biological processes such as wound healing,
vascular permeability, and angiogenesis among others. A
number of in vitro model systems have thus been devel-
oped to study EC activation that employs either one or
more combinations of ECM molecules including fibrin,
fibronectin, collagens, laminins, and Matrigel® matrices
together with PMA and FGF [7–9]. When placed in a 3D
type I collagen matrix and stimulated with PMA, VEGF, or
bFGF, ECs undergo rapid morphological changes and dif-
ferentiate into capillary-like tubular networks. Transcrip-
tional inhibitors block this in vitro tube formation,
suggesting that the angiogenesis requires EC activation
and gene expression [8,9]. Indeed, a recent review
describes approaches used to identify such angiogenesis-
related genes [10]. Although many angiogenesis-related
soluble factors, ECM components, and intracellular sign-
aling pathways have been identified and elucidated, their
subsequent targets and their mode of action still remain to
be determined.
Despite extensive studies, for example, the molecular
mechanisms underlying endothelial cell activation and
EC differentiations are not entirely understood. To better
understand molecular mechanisms and pathways of EC
activation, we embedded ECs in 3D type I collagen in
presence or absence of human recombinant VEGF165.
RNAs isolated from these cultures were then subjected to
suppression subtractive hybridization and differential dis-
play (SSHDD). Through this method, we identified a set
of 11 new induced genes previously not reported to be
associated with the processes of EC activation. We con-
firmed expressions of candidate genes in ECs by northern
and western blot analyses. There is a large number of lit-
erature showing microarray and gene-expression profiling
analysis of EC transcriptome. However, this preliminary
study forms the basis for the future experiments involving
analyses of signaling pathways associated with EC activa-
tion that are crucial for many pathophysiological condi-
tions including angiogenesis, cardiovascular diseases and
growth of solid tumors.
Results
Identification of VEGF-responsive endothelial cell genes 
using SSHDD
Angioblasts and ECs are the precursor cells that can form
functional blood vessels in response to specific angiogenic
stimuli. To study the molecular mechanisms underlying
capillary morphogenesis in ECs, we used a well-estab-
lished in vitro model of angiogenesis. Model system
employed in our study closely resembles with those that
have been described previously [7–9]. Either human
microvascular endothelial cells (HMECs) or human
umbilical vein endothelial cells (HUVECs) were seeded
between two thin layers of type I collagen gels, and over-
layed with complete media supplemented with VEGF165,
as described in methods. This typically induced cytoplas-
mic projections, spikes and extensions, elongations of ECs
within 4 to 8 hr. These processes were considered to rep-
resent a precursor to cell elongation, interconnections of
cells, and eventual tubule formation. A small population
of ECs that failed to elongate, did not form such intercon-
nections. This model system closely approximates ECM
proteolysis, cell migration, proliferation, and capillary
formation. Representative photomicrographs of VEGF-
induced capillary morphogenesis in ECs after 8 hr and 16
hr are shown in Figs. 1A and 1B, respectively. Figure 1C
shows ECs forming (at 200X magnification) elaborate
interconnections and vacuole formation at 36 hr.
Although control (un-stimulated) ECs formed intercon-
nections at the end of 24 hr, but fail to form any capillar-
ies (data not shown). Eosin staining of these structures
demonstrated that the capillaries were surrounded by at
least three to five ECs (Fig. 1D). To identify genes associ-
ated with activation of ECs, we used the method of
SSHDD. By employing forward- and reverse-subtraction,
we identified both common (indicated by arrows) and
differentially expressed genes (Fig. 1E &1F). The addition
of VEGF into ECs embedded in the 3D type I collagen
matrix (forward-subtraction) generated more than 450
cDNA fragments. To eliminate the identification of arti-
factual clones, we analyzed only those cDNA fragments
that were detected at least 4 times. Based on this criterion,
only 311 cDNA fragments (clones) out of 450 sequences
(clones) were retained for further evaluation. From this
311, a total number of 32 induced fragments were identi-
fied and sequenced (Table 1). Database search with these
nucleotide sequences using the BLAST algorithm revealed
many known positive or negative regulators of angiogen-
esis, including proteases and cell surface receptors. Impor-
tantly, we identified 11 VEGF-responsive candidate genes
associated with the activation of endothelial cells.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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Confirmation of Differentially Expressed Genes by 
Northern Blot
To confirm the differential expression of genes identified
by SSHDD, we performed Northern blot analysis of total
RNA isolated from ECs grown in 3D collagen matrices.
The expression of 5 known regulators of angiogenesis,
KDR and α2 integrin, VE-cadherin, MMP1, and MMP2, as
well as 11 candidate genes (Figs. 2, 4; Table 1) identified
were analyzed. Consistent with previous reports, the
expression of KDR/VEGFR-2 increased by ~2.5 fold at 12
hours, ~2 fold at 24 hrs, and ~1.5 fold at 36 hours, in
response to VEGF165 treatment (Fig. 2A), whereas the
expression of α2 integrin subunit was increased by ~5 fold
at 12 hours, by ~2 fold at 24 hrs, and was barely detectable
at 36 hrs (Fig. 2B) [11,12]. Expression of VE-cadherin was
minimal at the earlier time points, but significantly
increased at the end of 36 hours (Fig. 2C). MMP1 expres-
sion remained robustly active from 12 to 36 hours (Fig.
2D). While expression of MMP2 appeared to be biphasic,
highest expressions were detected at 12 and 36 hrs (Fig.
2E). Equal loading of RNAs was confirmed by probing
membrane with a β-actin cDNA probe (data not shown).
Northern analyses of clones 7D, 3B, 17E, 22G, 33A, 37F,
48A, 54C, 77D, 94H, 263F, and 309C were performed at
VEGF induced capillary morphogenesis of endothelial cells and dot blot screening Figure 1
VEGF induced capillary morphogenesis of endothelial cells and dot blot screening. HUVECs (3 × 105 cells/ml) were 
grown human recombinant VEGF165 (100 ng/ml), as described in Experimental Procedures. (A) Elongation and morphogenic 
changes of ECs after 8 hr exposure to VEGF; (B) ECs formed a mosaic of interconnecting networks after 16 hr of exposure to 
VEGF; (C) High resolution phase contrast phomicrograph of interconnected ECs developing vacuoles after 24 hr exposure to 
VEGF, as indicated by white arrowheads; and (D) cross section of an eosin-stained fixed gel, reveals the formation of capillary-
like structures after 36 hr exposure to VEGF (indicated by black arrowheads). White arrows indicate cell-contacts. Magnifica-
tion 100X. Bar, 50 µM. E, F) Escherichia coli cultures transformed with plasmids containing enriched cDNAs, were spotted 
from a 96-well dish onto duplicate nylon membranes. The membranes were hybridized with (E) forward-subtracted and (F) 
reverse-subtracted cDNA 32P-radiolabeled probes, as described in the "Methods". Black arrows indicate common genes 
detected by both probes.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
Page 4 of 12
(page number not for citation purposes)
24 hrs following VEGF165  treatment (Fig.
3A,3B,3C,3D,3E,3F,3G,3H,3I,3J,3K,3L). Northern blot
analysis did not support the differential expression of
clone 54C (Fig. 3H). Clone 7D, 3B, and 309C probes each
detected 2 transcripts, which could be either alternatively
spliced products or related genes. Clone 17E, 22G, 33A,
37F, 48A, 54C, 77D, 94H, 263F probes detected single
transcripts (Fig. 3C,3D,3E,3F,3G,3H,3I,3J,3K). Of particu-
lar note, probe 3B (corresponding to Stanniocalcin)
detected primarily the lower isoform (1.9 kb) in ECs.
While probe 309C (corresponding to Stabilin) is known
to produce three isoforms. Most likely, ECs primarily
express Stabilin-1 and -2 that are 7.8 and 6.2 kbs isoforms
respectively. The GAPDH probe was included as a control
for the quantity and integrity of the loaded RNA, detecting
a single transcript of ~1.3 kb. All data shown are represent-
ative of those obtained in at least three separate experi-
ments, with similar results.
Confirmation of Differentially Expressed Genes by 
Western Blot
To confirm that the genes identified by SSHDD encode
proteins, we performed Western blot analysis of total cel-
lular protein isolated from ECs grown in monolayers. The
addition of bFGF, VEGF, or PMA to the monolayers ECs
induced cellular elongation over a period of 8 to 24 hr. In
contrast, unstimulated ECs remained proliferative and
retained a cobblestone appearance (data not shown).
Western blot analysis revealed that VEGF and PMA, but
not bFGF, induced the expression of KDR, Flt-1, and the
α2 integrin subunit at 48 hr (Fig. 4A,4B,4C). Likewise,
only VEGF and PMA upregulated the expression of VE-
Cadherin (Fig. 4D). As expected, all 3 cytokines induced
Table I: Endothelial cell genes (ECG) detected by SSHDD. BLAST searches revealed similarity to the accession # provided on the right 
most column. Genbank accession number in bold letter denotes complete cDNA sequence deposited by the authors.
Class of genes Gen Bank Accession Number Reference
Known Genes associated with the activation of endothelial cells
Matrix metalloproteinases-1 (MMP-1) X54925 3,25,26
Matrix metalloproteinases-2 (MMP2) NM_ 004530 3,25,26
Stromelysin (MMP-3) X05232 2,3,25
Type IV collagenase (MMP9) J05070 2,3,26
Myeloblastin M75154 25,26
Cathepsin B M14221 28
Calpastatin E02261 29
Urokinase plasminogen activator surface receptor (uPAR) X51675 2,30
Vascular endothelial growth factor receptor (VEGFR1/FLT-1) AF063657 4,5
Vascular endothelial growth factor receptor-2(VEGFR-2/KDR) X61656 4,5,6
Vascular cell adhesion molecule-1 (VCAM-1) X53051 2,3
α2 integrin subunit X17033 2,20
VE-cadherin X79981 2,3,21
Prostaglandin endoperoxidase (Cox) E03346 2,32
Metabolic and miscellaneous genes
Ketohexokinase P50053 -
Adenosine deaminase X02994 -
Spermidine synthase M64231 -
Adenylyl cyclase X74210 33
Platelet factor 4 (PF4) M25897 34
Stanniocalcin U25997 35,36
Candidate genes associated with the activation of endothelial cells
Clone 7D Kinesin-heavy chain (KHC) X65873 37
Clone 17E Epiregulin (Epireg) NM_001432 38
Clone 22G Similar to transcription factor BTF3 XM_038290 40
Clone 33A Phosphatidic acid phosphatase-2b (PAP2b/VCIP) AB000889/AF480883 40,41
Clone 37F Synaptojanin-2 (similar to KIAA0348 protein) AB002346 42,43
Clone 48A Similar to GPCR kinase-interactor-2 (GIT-2) NM_014776 44
Clone 54C Smg GDS-associated protein (SMAP) AI401257/U59919 45
Clone 77D Angiopoietin related protein (AngRP) AF169312 46
Clone 94H Similar to Ribosomal protein L19 (RibL19) AB019566/BC013016 47,48
Clone 263F Eukaryotic translation EF-1 alpha l(EF-lal) BC028674 49
Clone 309C Stabilin-1 NM_015136 50Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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the expression of MMP-1 and MMP-2 (Fig. 4E and 4F).
These cytokines also induced expression of Kinesin (Fig.
4G), albeit less appreciably. Furthermore, we found dra-
matic increase in expression of VCIP/PAP2b in ECs that
were stimulated with VEGF and PMA (Fig. 4H, lane 3 and
4), in contrast, in bFGF stimulated cells (Fig. 4, lane 2) or
in control (Fig. 4, lane 1) its expression remained undetec-
table. Anti-Grb2 mAb was included as control for protein
loading (Fig. 4I). These data suggest that the cDNA frag-
ments detected by SSHDD were indeed active genes that
produce proteins that could activate endothelial cells.
Similar studies will be required to test whether remaining
novel genes produce functional proteins or not and to
establish their exact role in EC activation. For Western
immunoblotting experiment, monolayer ECs as opposed
to cells grown in 3D gel were used. Because, it was difficult
to solubilize ECs embedded in 3D gel. Cold cell extraction
buffer containing 1.25% Triton X-100 and 0.1% SDS did
not effectively solubilize solidified 3D collagen, - warm
(37°C) cell extraction buffer was incompatible because it
activated endogenous proteases. It remains possible that
different genes may be expressed in ECs cultured as mon-
olayer as opposed to 3D.
Discussion
In adult human, mature ECs usually remain quiescent for
3–7 years. However, ECs become activated in response to
inflammatory cytokines and growth factors and infec-
tions. Increased accumulation of these cytokines includ-
ing VEGF in the vasculature could activate the
transcription machinery of ECs. Despite large number of
studies activation of ECs and pathway that drive ang-
iogenic phenotype of adult or tumor angiogenesis remain
largely unknown [1–3]. Herein, we report identification
of a set of 11 candidate genes associated with the activa-
tion of ECs in vitro (Table 1). Other investigators have
used cDNA arrays and representational differential dis-
play methods to catalogue pattern of gene expression in
ECs that were stimulated with or without VEGF, bFGF,
and PMA [13–15]. We also provide evidence that these EC
gene fragments are induced in response to VEGF treat-
ment in 3D collagen gel, as illustrated by northern and
western blot analysis.
Known Regulators of Angiogenesis
Of the known regulators of EC activation identified in our
study, the role of MMPs has been well established. Matrix
digestion by MMPs, including MMP-1, MMP-2, and
MMP-9, is a pre-requisite for EC activation, differentia-
tion, and tumor induced angiogenesis [16,17]. The
growth of mesenchymal cells in a 3D type I collagen
matrix induces the processing and activation of pro-MMP-
2 by MMP-1. Consistent with this, incubation of ECs with
angiogenic cytokines induced the expression of MMP-1
and MMP-2 (Figs. 2 &4).
We also identified 4 indirect regulators of EC activation
and angiogenesis, i.e., myeloblastin, cathepsin B, calp-
astatin, and urokinase plasminogen activator surface
receptor (u-PAR). The myeloblastin protein displays anti-
proliferative properties and is also a key protease involved
in factor-independent growth of hematopoietic cells [18].
Overexpression of myeloblastin has been linked to multi-
functional cytokine transforming growth factor-β (TGF-β)
a known regulator of angiogenesis. We postulate that
myeloblastin in our model system may negatively regulate
EC activation, thereby signaling to end EC morphogenic
differentiation. Cathepsin B is a lysosomal cysteine
protease, the expression of which is increased in different
tumors, including human brain, lung, colon, and breast
tumors [19]. Calpastatin is a physiological protease
Northern confirmation of KDR, α2 integrin subunit, VE-cad- herin, MMP1, and MMP2 during activation of ECs Figure 2
Northern confirmation of KDR, α2 integrin subunit, 
VE-cadherin, MMP1, and MMP2 during activation of 
ECs. ECs were cultured in 3D collagen matrices with 
VEGF165. At various time points (indicated), total RNA was 
isolated and analyzed by Northern blot, as described in the 
"Methods". Blots were hybridized with indicated 32P-radiola-
beled probes. PCR primers used to generate probes are 
shown in Table 2. Data shown are representative of those 
obtained in two or three separate experiments, with similar 
results.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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Northern blot confirmation of VEGF-responsive genes Figure 3
Northern blot confirmation of VEGF-responsive genes. ECs were cultured in 3D collagen matrices with (+) or without 
(-) VEGF165. After 24 hours, total RNA was isolated and analyzed by Northern blot, as described in the "Methods". The 32P-
radiolabelled probes used and their corresponding GenBank accession numbers are indicated, and abbreviated gene names are 
given in perentheses (also see Table 1). The GAPDH probe was included as a control for the integrity and loading of the total 
RNA. Blots are representative of those obtained in two or three separate experiments, with similar results.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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Confirmation of gene expression as determined by Western blot analysis Figure 4
Confirmation of gene expression as determined by Western blot analysis. EC monolayers were either left untreated 
(lane 1) or were treated with 100 ng/ml of bFGF (lane 2), VEGF (lane 3), or 20 ng/ml PMA (lane 4) for 48 hours. Total cellular 
protein was extracted and analyzed by Western blot, as described in the "Methods". Blots were incubated with: (A) anti-KDR; 
(B) anti-F1t-1; (C) anti-α2 integrin subunit; (D) anti-VE-cadherin; (E) anti-MMPl; (F) anti-MMP2; (G) anti-Kinesin; (H) anti-
VCIP; and (I) anti-Grb2 antibodies. The molecular mass of each protein detected is indicated (kiloDaltons, kDa). Blots are rep-
resentative of those obtained in two or three separate experiments, with similar results.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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inhibitor that acts specifically on calpain, a calcium-
dependent cysteine protease. The cleavage of calpastatin
by caspases initiates the apoptotic cascade in certain neu-
rological disorders [20]. It is possible that increased
expression of calpastatin may control calpain activity
thereby limiting extent of proteolysis during capillary
sprouting. In contrast, uPAR has been shown to regulate
plasminogen-mediated extracellular proteolysis during
angiogenesis [21].
The identification of VEGFR-1 and VEGFR-2 (KDR) was
consistent with the observation that the stimulation of
ECs with VEGF increases the expression of VEGFR-2, pro-
moting myocardial revascularization [22]. We also
detected the cell adhesion molecules VCAM-1, VE-Cad-
herin, and the α2 integrin subunit, all known regulators of
angiogenesis. In the present study, we confirmed the
expression of KDR, α2 integrin, VE-cadherin, MMP1, and
MMP2 in activated ECs by northern and western blot
analysis (Figs. 2 and 4).
Finally, we identified a known modulator of angiogenesis,
the prostaglandin endoperoxidase-H synthase, also
known as cyclooxygenase (COX). The COX-1 isoform is
constitutively expressed in blood vessels, while expression
of the COX-2 isoform is induced in new blood vessels. In
many angiogenic tumors COX-2 colocalizes with VEGF
and TGF-β, and increased expression of COX-2 and VEGF
has been correlated with increased tumor microvascular
density [23].
Metabolic genes and Miscellaneous genes
Although metabolic genes such as ketohexokinase, adeno-
sine deaminase, and spermidine synthase detected by
SSHDD assay per se do not directly activate of EC, it is
likely that they could represent a component of the
"angiogenic switch". Among the miscellaneous genes
identified in our study were adenylyl cyclase and platelet
factor 4 (PF4). Intracellular signaling machinery of adeny-
lyl cyclase is required for cytoskeletal organization, vessel
maturation, and vessel integrity [24]. PF4 is a chemokine
that binds to FGF and is a known inhibitor of EC prolifer-
ation and migration [25]. Thus, the upregulation of PF4
might limit the degree of activation of ECs and morpho-
genic differentiation. It is noteworthy that Stanniocalcin
(Stc; accession # U25997; Figs. 3A) was also identified by
GeneCalling (a mRNA profiling technique) and in situ
hybridization demonstrated that Stc is expressed in the
vasculature of a subset of squamous cell carcinomas [26].
Stc is a secreted protein known to regulate calcium and
phosphate homeostasis, potential role of this protein in
EC activation and permeability is not clear [27]. Since
most ECM-degrading enzymes are metal ion dependent,
Stc may act as a sensor to maintain a steady-state level of
metal ions during EC activation.
Candidate genes associated with the activation of ECs
In addition to the genes discussed above that have previ-
ously been implicated in EC activation and differentia-
tion, we also identified 11 candidate genes (Table 1).
Kinesin heavy chain (KHC; accession# X65873; Figs. 3B
and 4G), mediates organelle movement towards the plus
ends of microtubules in the presence of ATP and functions
in cell differentiation and axonal guidance [28]. To our
knowledge, increased expression of KHC during EC differ-
entiation has not been previously reported. Although the
specific role of KHC in the differentiation process is
unclear, this protein might be important for the mainte-
nance of the plasticity and/or polarity of ECs, which may
be a prerequisite for the formation of capillary ends.
Epiregulin (Fig. 3C) is a member of epidermal growth fac-
tor (EGF) family of mitogens [29]. Expression of epiregu-
lin has been reported to be highest in placenta and in a
subset of carcinoma cells. Epiregulin activates COX-2,
therefore, epiregulin may serve as an upstream inflamma-
tory component of COX-2 signaling pathway. The func-
tion of epiregulin in the activation of ECs has not been
investigated.
A general transcription factor BTF3 (Fig. 3D, clone 22G,
accession #AA130020) protein is thought to be involved
in precise transcription by RNA polymerase II, but fails to
interact with DNA. Disruption of gene encoding BTF3
protein in the mouse caused postimplantation lethality
around embryonic day 6.5 [30]. Detailed studies have not
been reported in the literature. We believe, this is the first
report of identification of BTF3 as one of the induced
genes in the activation of ECs.
As a first step towards elucidating the molecular mecha-
nisms and pathways associated with activation of ECs, we
cloned the full-length cDNA corresponding to the Clone
33A called VCIP, also known as phosphatidic acid phos-
phatase type 2b (PAP2b). PAP2b shares similarity with
Drosophila  polarity gene Wunen-2  [31,32]. PAP2b/VCIP
encodes 311 amino acid residues, contains a single N-gly-
cosylation site, a consensus lipid phosphatase motif
(KPSXXXRPH), an RGD cell attachment motif, six-trans-
membrane channel-like structure, and displays Mg++ inde-
pendent lipid phosphatase activity in transfected 293T
cells [32]. Both N- and C-terminus segments of PAP2b/
VCIP are located inside the cytoplasm. Consistent with
previously published report our data suggest that PAP2b/
VCIP is cell surface protein and the expression of VCIP is
highly enriched in vascularized tissues. In addition to its
known lipid phosphatase activity, PAP2b/VCIP also
mediate cell-cell interactions [31].Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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Synaptojanin-2 (Figure 4F) is also known as a polyphos-
phoinositide phosphatase-2. This family of proteins is dis-
tant homolog of yeast protein SacI [33]. The SacI
homology domain is most notably found at the amino
terminal of the inositol 5'-phosphatase synaptojanin.
Synaptojanin-2 (lipid phosphatase) activities may be reg-
ulated by cell-cell and cell matrix interactions through
RAFTs 'morphogenetic' platforms [34].
G protein-coupled receptor (GPCR) kinase-interactor-2
(Fig. 3G) interacts with G protein-coupled receptor
kinases, and exhibits ADP-ribosylation factor (ARF)
GTPase-activating protein (GAP) activity. It is known have
several isoforms, alternatively sliced products, however,
we primarily detected a single transcript of 5.2 kb size (EC
specific isoform?). Because GIT-2 localizes with a subset
of paxillin, therefore, makes it a potential candidate
signaling protein that may collaborate with focal
adhesion signaling machinery [35]. Thus, GIT-2 may play
a role in cell adhesion, spreading, and motility.
SMAP, an Smg GDS-associating protein (Fig. 3H, Clone
54C, accession# AI401257), contains 9 Armadillo' repeats
and interacts with the smg GDS protein through these
repeats. This protein is a v-Src substrate, phosporylation
affects the affinity of the protein for smg GDS. The small
G protein GDP dissociation stimulator (smg GDS) acts on
a group of small G proteins including the Rho and Rap1
family members and Ki-Ras. Smg GDS exhibits dual activ-
ity. One is to stimulate their GDP/GTP exchange reac-
tions, and the other is to inhibit their interactions with
membranes [36].
Angiopoietin related protein (AngRP) (Fig. 3I) is chiefly
expressed by the hepatic cells. AngRP contain the charac-
teristic coiled-coil and fibrinogen-like domains that are
conserved in angiopoietins, however, do not interact with
Tie-1 and Tie-2 receptor [37]. AngRP act as a survival fac-
tor for ECs, but its role in angiogenesis is not clear. It will
be interesting to examine if there is a specific receptor for
this molecule in ECs or other vascular cells.
Probe 94H (Fig. 3J) detected 0.8 kb transcript, amino acid
sequence analysis suggest that this protein is likely to be
member of ribosomal protein L19 [38]. In eukaryotes,
ribosome consists of a 60S large subunit and a 40S small
subunit [39]. In mammalian cells, ribosomal proteins
accounts for up to 12% of the total cellular protein.
The alpha subunit of Translational elongation factor-1
(Fig. 3K) mediates binding of aminoacyl-tRNAs to 80S
ribosomes. This process is driven by hydrolysis of GTP
into GDP. Translational elongation factor-1 interacts with
guanine nucleotides, 80S ribosomes, and aminoacyl-
tRNAs. In addition, Translational elongation factor-1
binds with the β subunit of Translational elongation fac-
tor-1 to exchange bound GDP for GTP [41].
Finally, clone 309C (Fig. 3L) DNA sequence was identical
with stabilin-1. Stabilin has been described as an endothe-
lial-macrophage member of the fasciclin domain contain-
ing protein. Stabilin-1 and -2 are homologous
transmembrane proteins showing 7 fasciclin-like adhe-
sion domains, 18–20 EGF domains, 1 X-link domain and
3–6 B-X(7)-B hyaluronan-binding motifs [40]. Stabilin-1
and stabilin-2 are likely to play a role in cell-cell and cell-
matrix interactions in vascular cells [40].
Several articles describe the identification of genes associ-
ated with the activation of ECs and angiogenesis, as well
as the repertoire of genes expressed in normal versus
tumor-associated endothelium [42–45]. Because EC acti-
vation is a complex process, accompanied by alterations
in many aspects of EC physiology, it was not surprising
that the genes identified in these studies were in several
functional classes. However, the genes identified in the
present study are significantly different from those
reported by others, which may reflect differences in the
approaches used and types of tissues analyzed [42–45].
This preliminary study serves as groundwork for our labo-
ratory, and we believe, it will be worthwhile to examine
their role in ECs. Detail study of these candidate genes will
entail generation of recombinant cDNA constructs, gener-
ation of cell lines, antibodies, fusion proteins, and per-
form in-situ hybridization among others. Detailed
analysis of each of the differentially expressed genes iden-
tified in this report is ongoing and is beyond the scope of
this article.
Methods
Materials
HUVECs were purchased from Clonetics (CA). Most cell
culture reagents were purchased from InVitrogen Corp.
Oligonucleotide primers were purchased from Sigma-
Genosys; recombinant human VEGF (VEGF165), bFGF,
anti-VEGF (MAB293), and anti-MMP1 (MAB900) from
R&D Systems; adult human serum-AB, from Gemini Bio-
products; and bovine skin-derived type I collagen, from
Cohesion Inc. Affinity-purified anti-α2β1  integrin
(MAB1988), anti-αvβ3  integrin (LM609), anti-MMP2
(MAB13405), and anti-VE-cadherin (MAB1989) mono-
clonal antibodies (mAbs) were purchased from Chemi-
con Intl; anti-Flt-1 (sc-316), anti-KDR (sc-6251), anti-
Kinesin heavy chain (sc-13359), anti-Stanniocalcin (sc-
14352), and anti-Grb2 were obtained from Santa Cruz
Biotechnology Inc., and anti-β1 integrin subunit mAbs
(4B4), from Coulter Inc. Rabbit anti-α2 integrin subunit
polyclonal antibodies (pAbs) were a kind gift from Dr.
Guido Tarone (University of Torino Pavia, Italy). Anti-
MHC class II (W6/32) was purchased from Sigma. Anti-Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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VCIP/PAP2b-RGD antibody was generated by immuniz-
ing rabbit with a synthetic peptide modeled after 20
amino acid residues of VCIP/PAP2b (EGY-
IQNYRCRGDDSKVQEAR) [31].
Cell Culture
Monolayer cell culture was performed as previously
described [46,47]. To induce capillary formation,
unstarved proliferating HUVECs (passage 4) were gently
resuspended (at 6 × 105 cells/ml) in a 3D collagen matrix
that was prepared by mixing 7 ml of 3.0 mg/ml type I col-
lagen solution with 1 ml of 10X M199 medium at 4°C,
adjusting the pH to 7.5 with 0.1 N sodium hydroxide,
adding 0.1 ml of 100X ITS, and the final volume to 10 ml
with sterile distilled water. The cells were then seeded in
24-well tissue culture dishes and the matrix was allowed
to polymerize for 30 minutes at 37°C. The matrix was
subsequently layered with M199 medium containing
20% adult human serum-AB, 4 mM L-glutamine, 1X ITS,
and 100 ng/ml VEGF165. The growth medium was supple-
mented with fresh VEGF165 every 6 hours. The old growth
medium was removed and fresh medium + VEGF added
every 24 hours.
Suppression Subtractive Hybridization and Differential 
Display (SSHDD)
HUVECs were cultured in a 3D collagen matrix for 0, 12,
24, 36, 48, and 72 hours, with or without VEGF165 and
total RNA was extracted with TRIzol® Reagent (Invitrogen
Corp). Integrity of the RNA was determined by 1.2%
agarose-formaldehyde gel electrophoresis. Poly(A)+
mRNA was isolated from ~800 µg of total RNA using the
Table 2: Oligonucleotides used for generating PCR-probes. Genbank accession and their corresponding EST sequence numbers are 
given in parentheses. F and R denote forward and reverse primers.
Genes (accession number) Primers
α2 integrin (X17033 /NM_002203) (F) 5'-CTGTAGTAATGTTACCTGCTGGTT-3'
(R) 5'-GGTCTCATCAATCTCATCTGGATT-3'
KDR/VEGFR-2 (X61656) (F) 5'-GGTTCTGAGTCCGTCTCATGGAATTG-3'
(R) 5'-GTGTAATTTCCTGTGTCTCTTTCACTC-3'
VE-cadherin(X79981) (F) 5'-GATGTTCCCGGAGATCAGAAGACGTC-3'
(R) 5'-TGACTGATGCC ACTTCTCCAAGGTGTG-3'
MMP1 (X54925/NM_002421) (F) 5'-CTCTAGAGTCACTGATAC AC AG-3'
(R) 5'-CAGGGTGAC ACCAGTGACTGCAC-3'
MMP2 (NM_004530) (F) 5'-GC AGCCGTGCCTTCAGCTCTAC AG-3'
(R) 5'-GAAAGGAGAAGAGCCTGAAGTGT-3'
Clone 3B (U25997) (F) 5'-GGAC ACTGCCTTAGCCTCTTGGA-3'
(R) 5'-ATGC AAACTGGTCTAGGTCAGCC-3'
Clone 7D (X65873) (F) 5'-GGCATTCTGCACAGATTGCTAAAC-3'
(R) 5'-CCTAAGATGCC AAAATTGCACTC-3'
Clone 12F (BE468199/EST hz69e06.xl/) (F) 5'-GGACCAGAGCAGAAGGCCGAGCG-3'
(R) 5'-GGAAGGCCTCGTTAATATCCCGC-3'
Clone 22G (AA130020/EST zo40c12.rl) (F) 5'-GCTTCAGATTTACCAACAGCATG-3'
(R) 5'-GGAAGC ATTTCTGTGATTGGTTT-3'
Clone 33A (T35116/AF480883/EST80550) (F) 5'GGAGGATCCCTCGCGCCGCAGCCAGCGCCA-3'
(R) 5'-GTGGCACCTAC ATCATGTTGTGGTG-3'
Clone37F (XM_029746) (F) 5'-GGTTGATTAAATA ATCTTGACAATG-3'
(R) 5'-CCTTGAACTTC AACAACGTTAAAC-3'
Clone 48A (NM_014776) (F) 5'-GGCAGAGGTGCACTTTATGAAACT-3'
(R) 5'-ACGTTACCTTCAACCAGGACAAGG-3'
Clone 54C (AI401257/ESTtg86g04.xl) (F) 5'-GC AGTGTTTGTTTTCC AGTCTAG-3'
(R) 5'-GGCTATGGATCTTGATAAAGTAT-3'
Clone 77D (AF169312) (F) 5'-AGGACACGGCCTATAGCCTGCAG-3'
(R) 5'-AGAGGCGGCTCTTGGCGCAGTT-3'
Clone 94H (BC013016) (F) 5'-GGTC ACATGGATGAGGAGAATGA-3'
(R) 5'-TTGGATAAAGTCTTGATGATCTCC-3'
Clone 263F (BC028674) (F) 5'-GTATTGGATTGCCACACGGCTC A-3'
(R) 5'-CGATGCATTGTTATCATTAACCAG-3'
Clone 309 C (NM_015 136) (F) 5'-GCTTTGTGGAC AACATGACGCTGA-3'
(R) 3'-CC AAGCCAAGC AGTGCTCC AGCGGC-3'
GAPDH(M33197) (F) 5'-GGTCTCCTCTGACTTC AACAGCG-3'
(R) 5'-GGTACTTTATTGATGGTACATGAC-3'Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/25
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FastTrack® 2.0 mRNA Isolation Kit (Invitrogen Corp) and
cDNA was subsequently generated using random hexam-
ers as primers and SUPERSCRIPT II™ RNase H- Reverse
Transcriptase (Invitrogen Corp). The PCR-Select cDNA
Subtraction and PCR-Select Differential Screening Kits
(Clontech Laboratories Inc.) were used to enrich for and
identify differentially expressed genes in the driver and
tester cDNAs [48,49]. Both forward- and reverse-subtrac-
tion were performed; untreated HUVEC cDNA served as
driver and VEGF-treated HUVEC cDNA served as tester in
the former, whereas untreated HUVEC cDNA served as
tester and VEGF-treated HUVEC cDNA served as driver in
the latter [48,49]. Target cDNA fragments were amplified
using the Marathon™ cDNA Amplification Kit, subcloned
into pCR®2.1 using the TA Cloning® Kit and transformed
into TOP 10 One Shot™ competent cells (all from Invitro-
gen Corp). DNA sequencings were performed by Applied
Biosystems Model 373A (Lonestar Lab).
Northern Blot Analysis
HUVECs were cultured in a 3D collagen matrix for 0, 12,
24, and 36 hours, with or without VEGF165, as described
above. Northern blot analysis was performed as
previously described [31]. The KDR probe was amplified
from full-length KDR cDNA (available in our laboratory).
The other probes were amplified from untreated HUVEC
cDNA which was generated from total RNA by RT-PCR, as
described above. Oligonucleotide primers used for probe
amplification from cDNA are shown in Table 2.
Western Immunoblot Analysis
HUVEC monolayers were either left untreated or were
treated with 100 ng/ml of VEGF or bFGF, or with 20 ng/
ml of PMA every 6 hours for 48 hours. Monolayers were
then washed with cold PBS, pH 7.5, and solubilized in 1.0
ml of cell extraction buffer (50 mM HEPES, pH 7.5, 1%
Triton X-100, 0.1% SDS, 0.25% deoxycholate, 150 mM
sodium chloride, 1 mM EDTA, and protease inhibitors.
Equal quantities of clarified proteins were resolved by
SDS-PAGE under reducing conditions and transferred to a
nitrocellulose membrane. Antigen-antibody complexes
were detected as described previously [46,47].
Abbreviations
EC, endothelial cell; MMP, matrix metalloproteinases;
3D, three-dimensional; KDR, kinase domain receptor;
SSHDD, suppression subtractive hybridization followed
by differential display; VE-cadherin, vascular endothelial-
cadherin; PMA, phorbol 12-myristate 13-acetate; VEGF,
vascular endothelial growth factor; bFGF, basic fibroblast
growth factor.
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